<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004099</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40954</org_study_id>
    <secondary_id>EORTC-40954</secondary_id>
    <nct_id>NCT00004099</nct_id>
  </id_info>
  <brief_title>Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer</brief_title>
  <official_title>Randomized Phase III Study of Preoperative Chemotherapy Followed by Surgery Versus Surgery Alone in Locally Advanced Gastric Cancer (cT3 and cT4NxM0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known if surgery alone or surgery combined with
      chemotherapy is more effective in treating stomach cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without
      combination chemotherapy in treating patients who have stage II, stage III, or stage IV
      stomach cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare overall survival in patients with locally advanced gastric cancer treated with
           surgery alone or in combination with neoadjuvant cisplatin, leucovorin calcium and
           fluorouracil.

        -  Compare these two regimens in terms of the rate of complete resection, time to
           progression, and morbidity in these patients.

        -  Evaluate toxicity of and disease response to neoadjuvant chemotherapy in these patients.

        -  Evaluate quality of life and performance status in these patients pre- and post-surgery
           and compare quality of life for both regimens.

      OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified
      according to center, primary tumor category (cT3 or cT4), localization of tumor (upper third
      including cardia II or III vs middle and lower third), gender, and histological subtype
      (intestinal vs nonintestinal). Patients are randomized to one of two treatment arms.

        -  Arm I: Patients receive cisplatin IV over 1 hour on days 1, 15, and 29. Patients also
           receive leucovorin calcium IV over 2 hours followed by fluorouracil IV over 24 hours on
           days 1, 8, 15, 22, 29, and 36. A second course is administered beginning 2 weeks later
           in the absence of disease progression or unacceptable toxicity.

      Patients undergo resection and lymphadenectomy on days 57-63 of the second course of
      chemotherapy.

        -  Arm II: Patients undergo resection and lymphadenectomy within 14 days of randomization.

      Quality of life is assessed before randomization, every 3 months for 1 year and at 2 years
      after randomization.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, then every 3
      months thereafter until death.

      PROJECTED ACCRUAL: A total of 360 patients (180 per arm) will be accrued for this study over
      4 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>July 1999</start_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">144</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven stage II-IV adenocarcinoma of the stomach including cardia
             carcinoma types II and III

               -  Locally resectable disease

               -  No distant metastases except M1 lymph nodes

               -  No evidence of peritoneal carcinomatosis

                    -  Free tumor cells in lavage at laparoscopy allowed

          -  No uncontrolled bleeding of the primary tumor

          -  No gastric outlet syndrome or complete tumor stenosis that would require total
             parenteral nutrition

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 69

        Performance status:

          -  WHO 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 4,000/mm^3

          -  Absolute neutrophil count greater than 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  Prothrombin rate at least 70%

        Renal:

          -  Creatinine no greater than 1.25 times ULN

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular:

          -  No prior atrial or ventricular arrhythmias

          -  No prior congestive heart failure

          -  No myocardial infarction within the past 6 months

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other prior or concurrent neoplasm except curatively treated nonmelanoma skin
             cancer or carcinoma in situ of the cervix

          -  No active infection

          -  No allergy to protocol drugs

          -  No dementia or significantly altered mental status

          -  No other serious medical condition that would prevent compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No filgrastim (G-CSF) within 48 hours prior to chemotherapy

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  No prior stent implantation

          -  No prior laser therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Schuhmacher</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine III</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <zip>D-45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Bethesda Krankenhaus GmbH</name>
      <address>
        <city>Essen</city>
        <zip>D-45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik - Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik &amp; Poliklinik fur Strahlentherapie der Universitat zu Koln</name>
      <address>
        <city>Koln</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Meissen</name>
      <address>
        <city>Meissen</city>
        <zip>D-01657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfaelische Wilhelms-Universitaet</name>
      <address>
        <city>Muenster</city>
        <zip>DOH-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar/Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus</name>
      <address>
        <city>Solingen</city>
        <zip>D-42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Centro do Porto, SA</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <results_reference>
    <citation>Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010 Dec 10;28(35):5210-8. doi: 10.1200/JCO.2009.26.6114. Epub 2010 Nov 8.</citation>
    <PMID>21060024</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuhmacher C, Schlag P, Lordick F, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. [Abstract] J Clin Oncol 27 (Suppl 15): A-4510, 2009.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>intestinal adenocarcinoma of the stomach</keyword>
  <keyword>diffuse adenocarcinoma of the stomach</keyword>
  <keyword>mixed adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

